PART B - FEE(S) TRANSMITTAL

Complete and sand this form, together with applicable fee(s), to: Mail Or Fax					Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (703) 746-4000		
		smitting the ISSU				ired). Blocks 1 through 4 s	should be completed where
INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. On further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee configurations.							
CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) 7590 01/15/2004					Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.		
KAREN J. MESSICK, ESQ.					Certificate of Mailing or Transmission		
c/o PHARMACEUTICALS, INC. 1001 BRICKELL BAY DRIVE 25th FLOOR					I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.		
MIAMI, FL 33131					ARED G. SILBERHORD (Depositor's name)		
					(Signature)		
						1/20/04	(Date)
APPLICATION NO.	APPLICATION NO. FILING DATE FIRST NAMED INVE				TOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/962,027	10/31/1997	EUGENIO A. CEF			\LI	32892.23	8371
TITLE OF INVENTION: INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA							
APPLN. TYPE	SMALL ENTITY	ISSUE FEE		PU	BLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330			\$0	\$1330	04/15/2004
EXAMINER		ART UNIT		CL	ASS-SUBCLASS	J	
JOYNES, ROBERT M 1615 4					424-465000		
Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. DUFF Address in Justice (a. UFF) Address Indication form					a member a registered patent attorneys or matively, (2) the name of a single a member a registered attorney or names of up to 2 registered patent nts. If no name is listed, no name		
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)							
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)							
KOS PHARMACEUTICALS, INC. MIAMI, FL							
Please check the appropriate assignee category or categories (will not be printed on the patent);							
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):							
☐ Issue Fee ☐ A check in the amount of the fee(s) is enclosed.							
□ Publication Fee □ Payment by credit card. Form PTO-2038 is attached. □ Advance Order - # of Copies □ Payment by credit card. Form PTO-2038 is attached. □ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 500 - 7.5 13 (enclose an extra copy of this form).							
Director for Patents is reque	ested to apply the Issue Fee a	nd Publication Fee				ssue fee to the application id	· · · · · · · · · · · · · · · · · · ·
(Authorized Signature) (Date)						- 48	
NOTE; The Isue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.							
This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.							

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In rever plication of:

Eugenio A. Cefali

Serial No.:

08/962,027

Filing Date:

31 October 2003

Title:

INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA HAVING UNIQUE CMAX, TMAX AND AUC BIOPHARMACEUTICAL CHARACTERISTICS

Examiner:

Robert M. Joynes

Group Art Unit:

1615

'Attorney Docket Number:

50454-56103USCIP1

VIA FACSIMILE AND MAIL

1.703.746.4000 (2 pages being transmitted.)

MAIL STOP ISSUE FEE

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

ISSUE FEE TRANSMITTAL

Dear Sir:

In connection with the above-referenced United States Patent Application and with regards to the Notice of Allowance issued 15 January 2004, please charge the requisite Issue Fee of \$1330.00 to our Deposit Account No. 50-2543. A duplicate copy of this letter is enclosed herewith. No additional costs or fees are believed to be due in connection with this application, however, please charge any additional costs or credit any overpayment to this deposit account.

Respectfully submitted,

Kos Pharmaceuticals, Inc.

Karen J. Messick, Esq. Attorney for Applicants Registration No. 46,256

Kos Pharmaceuticals, Inc. 1001 Brickell Bay Drive

25th Floor

Miami, Florida 33131 Tel.: (305) 523.3643 Fax.: (305) 377.4076

Date: 1 20 04

CERTIFICATE OF MAILING (37 C. F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, Alexandria, VA 22313-1450 on the date indicated below,

Date: 1 20 04

Jared G. Silberhorn